2013 Year in Review

The Scripps Research Institute

Accelerating Discoveries, Saving Lives
DEVELOPING A DRUG CANDIDATE THAT PROTECTS HEART CELLS DURING AND AFTER ATTACK

Using two different experimental models, a team of scientists from Scripps’ Florida campus were able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against scarring damage from bouts of cardiac ischemia, which are the patients in the laboratory of Professor Philip Sharp. This finding, which is consistent with a risk for heart injury from blood flow after an attack. In a study published in Circulation in May, Sharp’s team found that a small-molecule inhibitor of GDF-15, a protein that women from the National Institute of Health (NIH), the research was funded by the National Institutes of Health (NIH). The research was funded by the National Institutes of Health (NIH). The research was funded by the National Institutes of Health (NIH). The research was funded by the National Institutes of Health (NIH). The research was funded by the National Institutes of Health (NIH). The research was funded by the National Institutes of Health (NIH). The research was funded by the National Institutes of Health (NIH).
FROM THE PRESIDENT

I am pleased to report that The Scripps Research Institute (TSRI) has made many remarkable research advances in 2013, highlighted in the pages that follow. We are committed to innovative science that leads to longer, healthier lives and to graduate education that will enable our students, the next generation of scientists, to make important discoveries.

Philanthropic funding is vital to this important work. With decreasing federal commitment, individuals, foundations and corporations are moving to fill the gaps—gaps that include supporting high-risk, high-return research, advancing emerging fields and speeding the application of research to patients in need.

Among the year’s gifts was a generous $2 million contribution from John Moores, former chair of TSRI’s Board of Trustees, to fund development of a revolutionary new field test for Onchocerciasis, or river blindness, a parasitic infection that affects tens of millions of people in tropical regions. We are also deeply grateful to Rich and Helen DeVos, who renewed their support of the graduate program at Scripps Florida by pledging $1.25 million for attracting, enriching and retaining outstanding Ph.D students.

Your gifts to TSRI support world-class research and education. Our faculty are at the top of their fields, as their numerous honors attest. In 2013, Phil Baran was one of only a handful of scientists selected as a MacArthur Fellow; Ardem Patapoutian was chosen for the highly competitive Howard Hughes Medical Institute Investigator award; Donna Blackmond was elected to the National Academy of Engineering; Peter Shultz won the Belgian Chemistry for the Future Solvay Prize; and Scott Hansen received a National Institutes of Health (NIH) New Innovator Award, to name just a few.

Our investigators also continue to successfully compete for major federal grants. In 2013, these included a $29 million renewal of a grant led by Professor Eric Topol at the Scripps Translational Science Institute to research genomics, wireless technology and bioinformatics for individualized medicine. In addition, a Scripps Florida team led by Professor Paul Robbins was awarded $10.6 million from the NIH to decipher the root causes of human aging.

With the continued backing of our friends and partners, we look forward to another exciting year in 2014. On the California campus, we are launching a powerful new Titan Krios cryo-electron microscope to provide our scientists with advanced three-dimensional imaging and analysis capabilities. In Florida, we begin celebrations marking the 10th anniversary of that campus—I am proud that, in a single decade, Scripps Florida has grown from an idea to a thriving center of research and education with deep roots as a community partner.

Thank you for your support and contributions, whatever the amount. Your participation is vital to the success of our endeavors to advance knowledge and improve human health.

Michael A. Marletta, PhD
President and CEO
Cecil H. and Ida M. Green Chair in Chemistry
The Scripps Research Institute

FINANCIAL HIGHLIGHTS

The Scripps Research Institute (TSRI) serves humanity by creating basic knowledge in the biosciences, applying breakthroughs in research to the advancement of medicine and drug discovery, and educating and training the next generation of scientists. Grants and contracts provide funding for a significant portion of the institute’s research activities; this revenue is derived primarily from the National Institutes of Health and other federal agencies. In addition, gifts from individuals and private foundations provide an important source of funding.

TSRI REVENUES, FISCAL YEAR 2013

- 81% Federal and other grants
- 5% Investment income
- 4% Licensing and royalties
- 2% Philanthropy

TSRI EXPENSES, FISCAL YEAR 2013

- 89% Biomedical research
- 6% Graduate school
- 4% Management/general
- 1% Fundraising/other

PHILANTHROPY REVENUE SOURCES FISCAL YEAR 2013

- 57% Individuals
- 20% Foundations
- 12% Planned giving/estates
- 3% Corporations

Thank you for helping us reach $9.3 million in philanthropy revenue in FY 2013! Your gifts help support TSRI’s life-saving research.

HOW TO REACH US

CA: The Scripps Research Institute
10550 North Torrey Pines Road, TPC-2
La Jolla, CA 92037
(858) 784-2915

FLA: 130 Scripps Way, 4B2
Jupiter, FL 33458
(561) 228-2015

www.scripps.edu
philanthropy@scripps.edu